RenovoRx Inc (RNXT) - Net Assets
Based on the latest financial reports, RenovoRx Inc (RNXT) has net assets worth $8.08 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.21 Million) and total liabilities ($3.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RNXT asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.08 Million |
| % of Total Assets | 72.09% |
| Annual Growth Rate | 25.03% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 470.99 |
RenovoRx Inc - Net Assets Trend (2019–2024)
This chart illustrates how RenovoRx Inc's net assets have evolved over time, based on quarterly financial data. Also explore RenovoRx Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for RenovoRx Inc (2019–2024)
The table below shows the annual net assets of RenovoRx Inc from 2019 to 2024. For live valuation and market cap data, see RNXT stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.48 Million | +249.27% |
| 2023-12-31 | $-3.00 Million | -148.68% |
| 2022-12-31 | $6.16 Million | -59.85% |
| 2021-12-31 | $15.35 Million | +204.73% |
| 2020-12-31 | $-14.66 Million | -1100.41% |
| 2019-12-31 | $1.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to RenovoRx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3905700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.04% |
| Other Components | $54.70 Million | 1221.42% |
| Total Equity | $4.48 Million | 100.00% |
RenovoRx Inc Competitors by Market Cap
The table below lists competitors of RenovoRx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inoviq Ltd
AU:IIQ
|
$32.37 Million |
|
HOYA Resort Hotel Group
TWO:2736
|
$32.38 Million |
|
Sakuma Exports Limited
NSE:SAKUMA
|
$32.38 Million |
|
Australian Gold and Copper Ltd
AU:AGC
|
$32.39 Million |
|
Elektrocieplownia Bedzin
WAR:BDZ
|
$32.36 Million |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
$32.35 Million |
|
Deliveroo Holdings PLC
LSE:ROO
|
$32.33 Million |
|
Aurora Mobile Ltd
NASDAQ:JG
|
$32.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RenovoRx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,000,000 to 4,478,000, a change of 7,478,000.
- Net loss of 8,814,000 reduced equity.
- New share issuances of 15,016,000 increased equity.
- Other comprehensive income decreased equity by 3,000,000.
- Other factors increased equity by 4,276,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.81 Million | -196.83% |
| Share Issuances | $15.02 Million | +335.33% |
| Other Comprehensive Income | $-3.00 Million | -66.99% |
| Other Changes | $4.28 Million | +95.49% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares RenovoRx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.44x to 4.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.08 | $0.88 | x |
| 2020-12-31 | $-0.85 | $0.88 | x |
| 2021-12-31 | $0.86 | $0.88 | x |
| 2022-12-31 | $0.34 | $0.88 | x |
| 2023-12-31 | $-0.15 | $0.88 | x |
| 2024-12-31 | $0.19 | $0.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RenovoRx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -196.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20497.67%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.81x
- Recent ROE (-196.83%) is below the historical average (-109.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -262.05% | 0.00% | 0.00x | 1.55x | $-3.99 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.33 Million |
| 2021 | -41.20% | 0.00% | 0.00x | 1.06x | $-7.86 Million |
| 2022 | -158.54% | 0.00% | 0.00x | 1.18x | $-10.39 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.93 Million |
| 2024 | -196.83% | -20497.67% | 0.01x | 1.81x | $-9.26 Million |
Industry Comparison
This section compares RenovoRx Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RenovoRx Inc (RNXT) | $8.08 Million | -262.05% | 0.39x | $32.36 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was… Read more